Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative.
European Journal of Cancer.
Times cited: 59
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Annals of Oncology.
Times cited: 68
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial.
Times cited: 1195